Intellia Therapeutics, Inc. (NTLA) income statement
NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3011% above fair value
$10.00+0.48 (+5.04%)
Close on Nov 20, 2026Market cap $1.40BP/E –Yield –
Intellia Therapeutics, Inc. financial ratios
See a number that looks wrong?